The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 81, Issue 4, 2016, Pages 589-604

  Bérard, Anick ^a,b   Iessa, Noha ^a,b   Chaabane, Sonia ^a,b   Muanda, Flory T ^a,b   Boukhris, Takoua ^a,b   Zhao, Jin Ping ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cardiac malformations; major malformations; meta analysis; paroxetine; pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR RISK; CONGENITAL MALFORMATION; DEPRESSION; FALLOT TETRALOGY; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SYSTEMATIC REVIEW; ABNORMALITIES, DRUG-INDUCED; ADVERSE EFFECTS; CHEMICALLY INDUCED; CONGENITAL HEART MALFORMATION; FEMALE; MATERNAL EXPOSURE; PREGNANCY; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; MATERNAL EXPOSURE; PAROXETINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 84956640345     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12849     Document Type: Article

References (65)

1. Marcus SM,. Depression during pregnancy: Rates, risks and consequences-motherisk update 2008. Can J Clin Pharmacol 2009; 16: E15-22.
2. Grigoriadis S, Robinson GE,. Gender issues in depression. Ann Clin Psychiatry 2007; 19: 247-55.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE,. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593-602.
4. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR,. Prevalence of depression during pregnancy: Systematic review. Obstet Gynecol 2004; 103: 698-709.
5. Silva R, Jansen K, Souza L, Quevedo L, Barbosa L, Moraes I, Horta B, Pinheiro R,. Sociodemographic risk factors of perinatal depression: A cohort study in the public health care system. Rev Bras Psiquiatr 2012; 34: 143-8.
6. Ahluwalia IB, Mack KA, Mokdad A,. Mental and physical distress and high-risk behaviors among reproductive-age women. Obstet Gynecol 2004; 104: 477-83.
7. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ,. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012-24.
8. O'Keane V, Marsh MS,. Depression during pregnancy. BMJ 2007; 334: 1003-5.
9. Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT,. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63: 830-4.
10. Henrichs J, Schenk JJ, Roza SJ, van den Berg MP, Schmidt HG, Steegers EA, Hofman A, Jaddoe VW, Verhulst FC, Tiemeier H,. Maternal psychological distress and fetal growth trajectories: The generation R study. Psychol Med 2010; 40: 633-43.
11. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I,. Pregnancy as a major determinant for discontinuation of antidepressants: An analysis of data from the health improvement network. J Clin Psychiatry 2011; 72: 979-85.
12. Cooper WO, Willy ME, Pont SJ, Ray WA,. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196: 544 e1-5.
13. Berard A, Sheehy O,. The Quebec pregnancy cohort-prevalence of medication use during gestation and pregnancy outcomes. PLoS One 2014; 9: E93870.
14. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T,. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 863-70.
15. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R,. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol 2008; 198: 194 e1-5.
16. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE,. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open 2012; 2: Doi: 10.1136/bmjopen-2012-001148
17. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT,. Increase in use of selective serotonin re-uptake inhibitors in pregnancy during the last decade, a population-based cohort study from The Netherlands. Br J Clin Pharmacol 2008; 65: 600-6.
18. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH Jr, Watson WJ,. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 2008; 28: 714-6.
19. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G,. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 1998; 279: 609-10.
20. Simon GE, Cunningham ML, Davis RL,. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61.
21. Malm H, Klaukka T, Neuvonen PJ,. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289-96.
22. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L,. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812-5.
23. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Norgaard M,. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design. BMJ 2015; 350: H1798.
24. Williams M, Wooltorton E,. Paroxetine (Paxil) and congenital malformations. CMAJ 2005; 173: 1320-1.
25. Reis M, Kallen B,. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010; 40: 1723-33.
26. Kallen BA, Otterblad OP,. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301-8.
27. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention S,. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-92.
28. Cole JA, Ephross SA, Cosmatos IS, Walker AM,. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 1075-85.
29. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D,. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 18-27.
30. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT,. First-trimester use of paroxetine and congenital heart defects: A population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88: 94-100.
31. Malm H, Artama M, Gissler M, Ritvanen A,. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118: 111-20.
32. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D,. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993-6.
33. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W,. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65: 230-7.
34. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, Stowe ZN,. Antidepressants in amniotic fluid: Another route of fetal exposure. Am J Psychiatry 2006; 163: 145-7.
35. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP,. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3: E2782.
36. Morrison JL, Riggs KW, Rurak DW,. Fluoxetine during pregnancy: Impact on fetal development. Reprod Fertil Dev 2005; 17: 641-50.
37. Gentile S,. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011; 123: 266-75.
38. Wurst KE, Poole C, Ephross SA, Olshan AF,. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010; 88: 159-70.
39. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE,. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013; 74: E293-308.
40. Myles N, Newall H, Ward H, Large M,. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013; 47: 1002-12.
41. Gentile S, Bellantuono C,. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: Focus on paroxetine. J Clin Psychiatry 2009; 70: 414-22.
42. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L, Doyle P, Hubbard RB, Tata LJ,. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: A population-based cohort study. BJOG 2014; 121: 1471-81.
43. Huybrechts KF, Palmsten K, Mogun H, Kowal M, Avorn J, Setoguchi-Iwata S, Hernandez-Diaz S,. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry 2013; 35: 265-71.
44. Knudsen TM, Hansen AV, Garne E, Andersen AM,. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth 2014; 14: 333.
45. Viera AJ,. Odds ratios and risk ratios: What's the difference and why does it matter? South Med J 2008; 101: 730-4.
46. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
47. Duval S, Tweedie R,. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-63.
48. Colvin L, Slack-Smith L, Stanley FJ, Bower C,. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91: 142-52.
49. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R, Hmo Research Network Center for Education RiT. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16: 1086-94.
50. Huybrechts KF, Hernandez-Diaz S, Avorn J,. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 371: 1168-9.
51. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA,. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-83.
52. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M,. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study. J Clin Psychopharmacol 2012; 32: 186-94.
53. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C,. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83: 68-76.
54. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH,. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 2009; 339: B3569.
55. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A,. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66: 695-705.
56. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G,. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749-52.
57. Chambers C,. Birth outcomes among pregnant women taking paroxetine (PAXIL). 2007.
58. Nash CM, O'Connell CM, Howlett AA,. Neonatal outcomes associated with maternal antidepressant use in a population cohort of Nova Scotian pregnancies between 1993 and 2004. Pediatr Child Health 2007; 12: 42.
59. Vial T, Cournot MP, Bernard N, Carlier P, Jonville-Bera P, Jean-Pastor MJ, Bajhoux C, Robert E, Elefant E, Descotes J,. Paroxetine and congenital malformations: A prospective comparative study. Drug Saf 2006; 29: 911-1010.
60. Schloemp S, Einarson TR, Sterzik K, Stox F,. Congenital malformations after antidepressant medication asociated with paroxetine in early pregnancy? Hum REprod 2006; 21 (Sup 1).
61. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS,. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy 2013; 33: 693-700.
62. Margulis AV, Abou-Ali A, Strazzeri MM, Ding Y, Kuyateh F, Frimpong EY, Levenson MS, Hammad TA,. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: A propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 2013; 22: 942-51.
63. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G,. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29: 918-26.
64. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K,. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184-91.
65. Tracy TS, Venkataramanan R, Glover DD, Caritis SN, National Institute for Child H, Human Development Network of Maternal-Fetal-Medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005; 192: 633-9.